Related Experiment Videos
[Cytokine production by gynecologic cancers]
1Frauenklinik am Klinikum Mannheim, Fakultät für klinische Medizin, Universität Heidelberg.
Geburtshilfe Und Frauenheilkunde
|March 1, 1991
Summary
Patients with breast and cervical cancer exhibit significantly reduced interferon-alpha (IFN-alpha) production. This impaired immune function, particularly IFN-alpha levels, persists post-treatment, suggesting chemotherapy
Area of Science:
- Immunology and Oncology
- Cytokine Research
Context:
- Gynaecological cancers, including breast and cervical cancer, show limited benefits from current aggressive treatments.
- Cytokine profiles are being investigated for potential immune-based therapeutic strategies.
Purpose:
- To evaluate the impact of gynaecological cancer on peripheral mononuclear cell (PBMC) cytokine production, specifically interferon-alpha (IFN-alpha), interferon-gamma (IFN-gamma), and tumor necrosis factor-alpha (TNF-alpha).
- To compare immune function in cancer patients against non-cancer controls and post-hysterectomy patients.
Summary:
- Tumor necrosis factor-alpha (TNF-alpha) production did not significantly differ across groups.
- Interferon-gamma (IFN-gamma) production was reduced in breast cancer patients, potentially due to chemotherapy and radiation.
- Both breast and cervical cancer patients demonstrated significantly reduced interferon-alpha (IFN-alpha) production before and up to three months after primary therapy, with chemotherapy further suppressing IFN-alpha levels.
Impact:
- The study highlights a critical deficit in IFN-alpha production in gynaecological cancer patients, indicating compromised immune function.
- Findings suggest that impaired IFN-alpha production may be a biomarker for cancer progression or treatment effects.
- Results support further investigation into immune therapies targeting IFN-alpha pathways for gynaecological cancers.